Hepatitis Forums

NASH Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on December 16, 2019, 11:45:42 am

Title: Emricasan Proves a Disappointment as NASH Treatment
Post by: Hep Editors on December 16, 2019, 11:45:42 am
Conatus Pharmaceuticals’ oral pan-caspase inhibitor emricasan proved disappointing as a potential treatment for non-alcoholic steatohepatitis (NASH) in a 72-week trial. The treatment did not meet its primary endpoint of an improvement in liver fibrosis (scarring) of at least one stage without any worsening of NASH.

Stephen A. Harrison, MD, of Pinnacle Clinical Research in San Antonio, presented findings from the trial at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases, this week in Boston.

The randomized, placebo-controlled, double-blind study enrolled people at 87 sites in the United States, Spain and Germany. The participants had to have NASH, a non-alcoholic fatty liver disease activity score (NAS) of 4 or greater and a fibrosis stage of F1, F2 or F3. No more than 20% of the study population could have fibrosis Stage 1, and if they did, they also had to have diabetes or metabolic syndrome. If participants were taking vitamin E or pioglitazone, they had to be on a stable dose for at least three months.

Read more...
https://www.hepmag.com/article/emricasan-proves-disappointment-nash-treatment